USANA Health Sciences Inc (USNA)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 42,030 | 63,788 | 69,350 | 116,505 | 124,664 |
| Total stockholders’ equity | US$ in thousands | 532,109 | 497,202 | 434,472 | 395,124 | 441,650 |
| ROE | 7.90% | 12.83% | 15.96% | 29.49% | 28.23% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $42,030K ÷ $532,109K
= 7.90%
USANA Health Sciences Inc's return on equity (ROE) has shown some fluctuations over the years. From December 31, 2020, to December 31, 2021, the company experienced a slight increase in ROE from 28.23% to 29.49%, indicating improved efficiency in generating profits from shareholders' equity.
However, in the following years, USANA's ROE experienced a decline. By December 31, 2022, the ROE decreased to 15.96%, and further declined to 12.83% by December 31, 2023. This downward trend suggests a reduction in the company's ability to generate profits relative to shareholders' equity.
By December 31, 2024, USANA's ROE dropped to 7.90%, indicating a significant decrease in profitability efficiency compared to previous years. It is essential for USANA to assess and address the factors contributing to this decline in ROE to improve the company's financial performance and shareholder value in the future.